免疫健全且允许腺病毒复制的叙利亚仓鼠胶质瘤模型用于评估Delta-24-RGD
研究利用叙利亚仓鼠构建首个颅内胶质瘤模型,该模型既允许腺病毒复制又具备免疫健全性。方法为将仓鼠神经干细胞经hTERT、SV40大T抗原和h-RasV12转化获得仓鼠胶质瘤干样细胞(hamGSCs),并建立颅内肿瘤模型。结果显示hamGSCs在体外支持病毒复制并被Delta-24-RGD杀伤,体内成瘤呈高级别胶质瘤特征,Delta-24-RGD感染后T细胞浸润显著增加,且较PBS治疗显著延长生存。
要点
- 新型仓鼠胶质瘤模型同时允许腺病毒复制和免疫反应评估
- Delta-24-RGD在体外可杀伤hamGSCs并复制
- Delta-24-RGD体内治疗增加T细胞浸润并延长生存
核心结论
- 该腺病毒允许且免疫健全的仓鼠胶质瘤模型克服了既往模型局限,为研究肿瘤细胞、宿主免疫与溶瘤腺病毒治疗相互作用提供新平台。
研究设计与样本
- 用hTERT、猴病毒40大T抗原和h-RasV12转化仓鼠神经干细胞获得hamGSCs,经导引螺钉系统建立仓鼠颅内肿瘤模型。
主要发现
- hamGSCs在体外支持病毒复制并对Delta-24-RGD介导的细胞死亡敏感。
- hamGSCs在体内持续形成类似高级别胶质瘤的高增殖性肿瘤。
- 流式细胞术分析显示Delta-24-RGD感染的仓鼠胶质瘤中T细胞浸润显著增加,提示免疫激活。
- Delta-24-RGD治疗荷瘤仓鼠较磷酸盐缓冲液(PBS)治疗显著延长生存。
临床怎么用
- 该模型可用于临床前评估溶瘤腺病毒在免疫健全宿主中的疗效与免疫机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent. METHODS: We generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry. RESULTS: In vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS). CONCLUSIONS: This adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic.
引用
- Phillips LM, Li S, Gumin J, et al. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol. 2021. PMID: 34059921. doi:10.1093/neuonc/noab128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。